Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02054429 · ClinicalTrials.gov registry record · Phase 1

Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke

A Phase 1 study, sponsored by University at Buffalo.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT02054429 is a Phase 1 study that has completed, run by University at Buffalo. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02054429, a Phase 1 study, has completed, sponsored by University at Buffalo.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

The purpose of this study is to determine the safety and efficacy of lowering glucose (blood sugar), in addition to endovascular therapy, after acute ischemic stroke. The study will determine if lowering glucose (blood sugar) in addition to endovascular therapy will improve 90-day functional and neurological outcomes in comparison to standard glycemic care in patients with acute ischemic stroke. The study will involve treatment of 100 (50 intensive insulin therapy and 50 standard glycemic control) non-diabetic patients presenting within 8 hours of acute ischemic stroke who have undergone endovascular therapy.

Interventions

  • DRUG Insulin

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2013-01
Est. Completion 2016-12-31
Phase Phase 1

Sponsor

University at Buffalo

67 total trials

What the Registry Record Tells You About NCT02054429

The ClinicalTrials.gov registry entry for NCT02054429 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Insulin is the first listed.

NCT02054429 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02054429 about?

NCT02054429 is a clinical study titled "Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke". The purpose of this study is to determine the safety and efficacy of lowering glucose (blood sugar), in addition to endovascular therapy, after acute ischemic stroke. The study will determine if lowering glucose (blood sugar) in addition to endovascular therapy will improve 90-day functional and neu...

What is the current status of trial NCT02054429?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-01. Estimated completion is 2016-12-31.

What interventions are being tested in trial NCT02054429?

The interventions under investigation include: Insulin (DRUG).

Who is sponsoring clinical trial NCT02054429?

This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.